Skip to main content

Table 3 Relation between aspirin dose and risk of UGIB and perforation among current users as compared to non-use

From: Risk of upper gastrointestinal bleeding and perforation associated with low-dose aspirin as plain and enteric-coated formulations

  All cases Controls Adjusted RR*
  (N=2,105) (N=11,500) (95%CI)
Daily dose as instructed    
   75 mg 141 420 1.9 (1.6-2.4)
   150 mg 84 245 2.0 (1.5-2.6)
   300 mg$ 54 163 2.0 (1.4-2.8)
   600 + mg 8 9 4.0 (1.4-11.5)
Average daily dose +    
   <50 mg (irregular use) 4 29 0.7 (0.2-2.0)
   51-111 135 383 2.1 (1.7-2.6)
   112-225 91 258 1.9 (1.5-2.5)
   226-400 48 151 2.0 (1.4-2.9)
   > 400 9 16 3.1 (1.3-7.5)
  1. * Adjusted for sex, age, calendar year, antecedents of gastrointestinal disorders, smoking status, alcohol consumption and use of NSAIDs, anticoagulants, steroids, SSRIs and paracetamol. Additional adjustment for use of antiulcer drugs (antacids, H2-blockers and omeprazol) did not change the estimates. $ Five cases and three controls taking 300 mg in alternate days were included in this category. Assigning those patients to the 150-mg category hardly modified the results. + Calculated by dividing the number of tablets supplied over the treatment period. For 161 patients (51 (18%) cases and 110 (13%) controls) less than 3 prescriptions of aspirin were written, therefore the instructed dose was still considered in these patients.